Firma WELDING, Autor bei PR-Web

WELDING Group Publishes First Standardized Sustainability Report

Posted on 6. November 2026 by Firma WELDING Posted in General Tagged carbon, concrete, ecovadis, fiscal, future, gas, measures, media, report, resource, safety, SCHUMANN, sustainability, welding, with

WELDING GmbH & Co. KG is proud to present its first standardized sustainability report for the 2025/26 fiscal year, developed in collaboration with neqon. The report is publicly available on our website and gives all interested parties a clear view […]

WELDING PHARMA API and CHEMISCHE FABRIK BERG Announce Exclusive Partnership for Lisdexamfetamine

Posted on 29. September 2026 by Firma WELDING Posted in General Tagged API manufacturing, CHEMISCHE FABRIK BERG, CPhI Milan 2026, drug development, global pharmaceutical market, GMP-compliant, lisdexamfetamine, Lisdexamfetamine dimesilate, market access, pharmaceutical APIs, pharmaceutical partnership, Regulatory Compliance, Supply Chain, therapeutic innovation, WELDING PHARMA API

WELDING PHARMA API is proud to announce an exclusive partnership with CHEMISCHE FABRIK BERG for the development, manufacture and commercialization of Lisdexamfetamine dimesilate. Building on more than two decades of trusted collaboration in pharmaceutical APIs, this strategic partnership marks a […]

Deepening Technical Expertise in Pet Food

Posted on 8. September 2026 by Firma WELDING Posted in Industrial Engineering Tagged digestibility, extrusion, feedstock, gelling agents, high quality, microencapsulation, nutraceuticals, palatability, pet food, reliable, sensoryanalysis, shelf-life, stabilizers, technical expertise, training session

WELDING FEED, part of the WELDING Group, is deepening its collaboration with WELDING FOOD and its partner Eurogum – Bang & Bonsomer. By combining feed and food expertise, the partners support pet food manufacturers in developing reliable, high-quality products. Following […]

Quinine 200 mg Film-Coated Tablets (DCP Start)

Posted on 2. September 202620. October 2026 by Firma WELDING Posted in General Tagged 200 mg, antimalarial, biosimilar, commercialization, dcp, Decentralized Procedure, Film-Coated Tablets, generic medicines, medicinal formulation, pharmacovigilance, product licensing, Quinine, quinoline, regulatory approval, Supply Chain

Quinine 200 mg Film-Coated Tablets (DCP Start) The company has started the Decentralized Procedure (DCP) for Quinine 200 mg Film-Coated Tablets, marking a new step in the expansion of its European generic portfolio. Building on decades of experience in […]

WELDING GmbH & Co. KG, through its business unit PHARMA FDF, announces its first European marketing authorizations for Tafamidis 61 mg soft capsules

Posted on 29. May 2026 by Firma WELDING Posted in General Tagged biosimilar development, Decentralized Procedure, drug registration, EMA approval, generic medication, international pharma market, market authorization, marketing authorizations, multi country generic approval, pharmaceutical licensing, regulatory expertise, regulatory pathway, supply resilience, Tafamidis 61 mg soft capsules, value-based partnerships

WELDING GmbH & Co. KG announces an important regulatory milestone in Europe. Following the successful closure of the Decentralized Procedure (DCP) earlier this year, WELDING GmbH & Co. KG in collaboration with its partner Zenara Pharma Pvt Ltd has received its […]

WELDING GmbH & Co. KG Expands to Latin America

Posted on 27. May 2026 by Firma WELDING Posted in General Tagged Active Pharmaceutical Ingredients, competitive pricing, distribution expertise, Food Additives, functional nutrition, ingredient sourcing, international subsidiary, Latin American market, manufacturing standards, market expansion, mexico, pharmaceutical distribution, Regulatory Compliance, supply chain resilience, traceability systems

WELDING GmbH & Co. KG announces the establishment of its Mexican subsidiary, WELDING Ingredientes SA de CV. With this step, our family-owned company is expanding its international presence and strengthening its position in the Latin American market. Our goal is […]

Revio Therapeutics and Welding Group Announce Strategic Co-Development and Licensing Agreement for Innovative Specialty Oncology Product

Posted on 24. March 202624. March 2026 by Firma WELDING Posted in General Tagged biotechnology, cancer, drug development, healthcare innovation, market access, oncology, partnership, patient care, Regulatory Compliance, Revio, specialty pharmaceuticals, therapeutics

Revio Therapeutics ("Revio") and Welding Group ("Welding") today announced the signing of a co-development and licensing agreement for Revio’s proprietary specialty oncology product. The 505(b)(2) product, designed based on an innovative dosage form with significant patient compliance and ease-of-use advantages, will be developed […]